Acute febrile neutrophilic dermatosis in the setting of pembrolizumab in a patient with nonsmall cell lung cancer
DOI:
https://doi.org/10.5070/xszcfs74Keywords:
sweet syndrome, checkpoint inhibitor, neutrophilic dermatosisAbstract
Sweet syndrome, or acute febrile neutrophilic dermatosis is an inflammatory condition that may be idiopathic, paraneoplastic, parainflammatory, or drug associated. Recently, immune checkpoint inhibitors have been implicated in Sweet syndrome. Herein, we describe a patient with nonsmall cell lung cancer who developed Sweet syndrome in the setting of the immune checkpoint inhibitor, pembrolizumab. We also include a discussion of current literature of immune checkpoint inhibitors-induced Sweet syndrome and the histopathologic differential diagnosis of Sweet syndrome.
Downloads
References
1. Cohen PR. Sweet's syndrome--A comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis. 2007;2:34. [PMID: 17655751].
2. Vashisht P, Goyal A, Hearth Holmes MP. Sweet syndrome. [Updated 2022 Sep 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls; 2023. [PMID: 28613704].
3. Wongvibulsin S, Pahalyants V, Kalinich M, et al. Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis. J Am Acad Dermatol. 2022;86(3):563-572. [PMID: 33819538].
4. Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021 Jan 24;16:223-249. Epub 2020. [PMID: 33197221].
5. Martel J, Hanania HL, Patel AB. Immune checkpoint inhibitor-induced cutaneous toxicities: A review of histopathologic and clinical features. Hum Pathol. 2023 Oct;140:144-172. Epub 2023. [PMID: 37141978].
6. Tsibris H, Lian C, Ho A. Pembrolizumab-associated pyoderma gangrenosum in a patient with metastatic squamous cell carcinoma. Dermatol Online J. 2021;27(4):13030/qt4hs6n388. [PMID: 33999581].
7. Wang LL, Patel G, Chiesa-Fuxench ZC, et al. Timing of onset of adverse cutaneous reactions associated with programmed cell death protein one inhibitor therapy. JAMA Dermatol. 2018;154(9):1057-1061. [PMID: 30027278].
8. Ravi V, Maloney NJ, Worswick S. Neutrophilic dermatoses as adverse effects of checkpoint inhibitors: A review. Dermatol Ther. 2019 Sep;32(5):e13074. Epub 2019. [PMID: 31444856].
9. Zheng S, Li S, Tang S, et al. Insights into the characteristics of sweet syndrome in patients with and without hematologic malignancy. Front Med (Lausanne). 2020;7:20. [PMID: 32133363].
10. Xie Y, Lai D, Ke J, Zhao Z, Lin W. Sweet's syndrome with adenocarcinoma of lung: a rare case report. Ann Transl Med. 2023 Jan 31;11(2):133. doi: 10.21037/atm-22-5934. Epub 2023. [PMID: 36819515].
11. Raza S, Kirkland RS, Patel AA, Shortridge JR, Freter C. Insight into Sweet's syndrome and associated-malignancy: a review of the current literature. Int J Oncol. 2013;42(5):1516-22. [PMID: 23546524].
12. Szatkowski J, Schwartz RA. Acute generalized exanthematous pustulosis (AGEP): A review and update. J Am Acad Dermatol. 2015;73(5):843-8. [PMID: 26354880].
13. Crowson AN, Mihm MC Jr, Magro C. Pyoderma gangrenosum: A review. J Cutan Pathol. 2003;30(2):97-107. [PMID: 12641787].
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Aman Nihal, Susan Pei, Shanon Lacy, Linda Serrano (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
